Skip to main content
. 2019 Jun;8(3):268–279. doi: 10.21037/tlcr.2019.06.12

Figure 3.

Figure 3

The subgroup analyses of intracranial progression-free survival (iPFS) depend on EGFR mutation subtype (A), patients age (B) and BM-related (symptomatic vs. asymptomatic) (C); HR, hazard ratio; BM, brain metastases; RT, radiotherapy; TKIs, tyrosine kinase inhibitors; EGFR, epidermal growth factor receptor.